Oiceridine

PreclinicalSmall molecule

XXijing Hospital

Oiceridine is one of 4 small molecule programs targeting Oliceridine Fumarate. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oliceridine FumarateRecruiting

Oliceridine FumaratePreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in Oliceridine Fumarate

#DrugCompanyPhaseTrials

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 2

Oliceridine Fumarate

CChun Pan

Phase 3

1 3

Sufenta

LLeaf Vertical Inc.

Preclinical

1 4

Oiceridine

XXijing Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Oliceridine Fumarate

NCT07307495

Clinical

Trials by Indication[1]

Oliceridine Fumarate1 trial

Effect of Postoperative Analgesia of Oliceridine Fumarate for Gastrointestinal Function Recovery in Patients Undergoing Lumbar Spine Surgery:A Prospective, Multicenter, Double-blind,Randomized Controlled Study

Recruiting·XXijing Hospital·Preclinical·NCT07307495·428 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Oiceridine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oiceridine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oiceridine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xijing Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: XXijing Hospital

Oiceridine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Oliceridine Fumarate1 trial

References

Drug Info

Quick Facts

Related News